Trent A.  Basarsky net worth and biography

Trent Basarsky Biography and Net Worth

Dr. Trent Basarsky is the Vice President of our Commercial business. Trent is a marketing and business executive with more than 20 years of experience in the life sciences sector. Prior to joining 908 Devices, Trent was the Chief Business Officer at Zephyrus Biosciences, the developers of a single cell western platform, which was acquired by BioTechne in 2016. Previously Trent was the VP of Corporate Development at ProteinSimple, a company focused on protein analysis instrumentation, where his responsibilities in corporate development, marketing and intellectual property helped grow the company to over $55M in revenue prior to the successful sale of the company for $300M. Trent served as the Director of Corporate Development at Codexis, a cleantech company focused on next-generation biofuels and pharmaceutical manufacturing. Before joining Codexis, he was Director of Corporate Development at Molecular Devices and helped grow the business to more than $180M prior to the sale of the company for over $600M. He also held positions in marketing, product management, business development and intellectual property at Axon Instruments, which was acquired by Molecular Devices. Trent holds a Ph.D. in Neuroscience from Iowa State University, a B.Sc. in Zoology from the University of Alberta, and is a registered patent agent. He enjoys endurance mountain bike racing, playing competitive hockey, and golf.

What is Trent A. Basarsky's net worth?

The estimated net worth of Trent A. Basarsky is at least $521,250.00 as of April 12th, 2022. Dr. Basarsky owns 75,000 shares of 908 Devices stock worth more than $521,250 as of March 27th. This net worth evaluation does not reflect any other investments that Dr. Basarsky may own. Learn More about Trent A. Basarsky's net worth.

How do I contact Trent A. Basarsky?

The corporate mailing address for Dr. Basarsky and other 908 Devices executives is , , . 908 Devices can also be reached via phone at 857-254-1500 and via email at [email protected]. Learn More on Trent A. Basarsky's contact information.

Has Trent A. Basarsky been buying or selling shares of 908 Devices?

Trent A. Basarsky has not been actively trading shares of 908 Devices during the last quarter. Most recently, Trent A. Basarsky sold 15,000 shares of the business's stock in a transaction on Tuesday, April 12th. The shares were sold at an average price of $19.74, for a transaction totalling $296,100.00. Following the completion of the sale, the vice president now directly owns 75,000 shares of the company's stock, valued at $1,480,500. Learn More on Trent A. Basarsky's trading history.

Who are 908 Devices' active insiders?

Are insiders buying or selling shares of 908 Devices?

In the last year, insiders at the sold shares 6 times. They sold a total of 40,346 shares worth more than $324,982.08. The most recent insider tranaction occured on February, 1st when insider Michael S Turner sold 5,232 shares worth more than $36,571.68. Insiders at 908 Devices own 27.8% of the company. Learn More about insider trades at 908 Devices.

Information on this page was last updated on 2/1/2024.

Trent A. Basarsky Insider Trading History at 908 Devices

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/12/2022Sell15,000$19.74$296,100.0075,000View SEC Filing Icon  
3/14/2022Sell15,000$17.66$264,900.00View SEC Filing Icon  
9/23/2021Sell6,000$37.70$226,200.00View SEC Filing Icon  
8/27/2021Sell2,003$34.96$70,024.88View SEC Filing Icon  
8/24/2021Sell10,078$34.95$352,226.10View SEC Filing Icon  
7/23/2021Sell21,000$32.25$677,250.0047,000View SEC Filing Icon  
See Full Table

Trent A. Basarsky Buying and Selling Activity at 908 Devices

This chart shows Trent A Basarsky's buying and selling at 908 Devices by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

908 Devices Company Overview

908 Devices logo
908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling. Its products also comprise Maven and Trace C2, an online device for bioprocess monitoring and control; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. The company operates in the United States, Europe, the Middle East, Africa, the Asia Pacific, and rest of the Americas. 908 Devices Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $6.95
Low: $6.43
High: $6.98

50 Day Range

MA: $7.18
Low: $6.55
High: $8.29

2 Week Range

Now: $6.95
Low: $4.85
High: $12.51

Volume

188,703 shs

Average Volume

174,005 shs

Market Capitalization

$228.72 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.92